Overview
QNRX market data
Price History
QNRX price chart · 1M
- O
- 4.93
- H
- 4.93
- L
- 4.71
- C
- 4.73
- Vol
- 545.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $4.93
- Previous Close
- $5.22
- Day High
- $4.93
- Day Low
- $4.71
- 52 Week High
- $6.31
- 52 Week Low
- $3.47
- 7 Day Return
- -9.47%
- 30 Day Return
- +11.29%
- 90 Day Return
- -6.15%
- 1 Year Return
- -17.52%
- Daily Notional Volume
- $2.6K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$14.80 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.54 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $3.25 – $41.80 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $11.6M · P/B 0.61.
Company News
8-K filing — Quoin Pharmaceuticals, Ltd. (QNRX)SEC EDGAR · Aug 20, 2026, 8:19 PM
12 Health Care Stocks Moving In Friday's Intraday SessionBenzinga · Aug 14, 2026, 5:06 PM
Quoin Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 results.Benzinga · Aug 14, 2026, 3:11 PM
Quoin Pharmaceuticals Q2 EPS $(1.90) Misses $(1.61) EstimateBenzinga · Aug 14, 2026, 12:33 PM
Quoin Pharmaceuticals Receives FDA Clearance Of Its Investigational New Drug Application For QRX003 To Treat Peeling Skin SyndromeBenzinga · Jul 9, 2026, 12:40 PM
Quoin Pharmaceuticals Issued Notice Of Allowance From U.S. Patent And Trademark Office Titled Combination Treatment For Netherton SyndromeBenzinga · Jun 30, 2026, 12:35 PM
Quoin Pharmaceuticals Receives FDA's Conditional Approval For QYLEKI To Treat Netherton SyndromeBenzinga · Jun 23, 2026, 12:40 PM
Quoin Pharmaceuticals Establishes Japanese Subsidiary To Commercialize QRX003 For The Treatment Of Netherton Syndrome Upon Approval By AuthoritiesBenzinga · Jun 18, 2026, 12:45 PM
Quoin Pharmaceuticals Announces That Four Of Six Children In Its Ongoing Pediatric Netherton Syndrome Compassionate Use Study Were Classified As 'Improved' Or 'Significantly Improved' From Baseline Across Key Clinical EndpointsBenzinga · Jun 16, 2026, 12:40 PM
Quoin Pharmaceuticals QRX003 Receives Japan's Ministry Of Health, Labour And Welfare To Treat Netherton SyndromeBenzinga · Jun 4, 2026, 12:50 PM